SCHEDULE 13G: Point72 Entities Disclose 5.1% Passive Stake in Oric Pharmaceuticals
Beneficial Ownership Disclosure
Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen have jointly disclosed a 5.1% passive beneficial ownership stake in Oric Pharmaceuticals, Inc., including shares from warrants.
Summary
- Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have jointly filed a Schedule 13G, disclosing their beneficial ownership in Oric Pharmaceuticals, Inc.
- The reporting persons collectively beneficially own 4,401,659 shares of Oric Pharmaceuticals, Inc. common stock.
- This ownership represents 5.1% of the total outstanding shares of Oric Pharmaceuticals, Inc.
- The reported shares include 1,923,107 shares that are issuable upon the exercise of warrants.
- The beneficial ownership percentage is calculated based on 87,141,500 total shares outstanding as of June 3, 2025, which accounts for shares disclosed in the Issuer's recent 10-Q and 8-K filings, including a private placement.
- The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The filing is a standard passive ownership disclosure. The presence of a significant stake by a prominent institutional investor like Point72 Asset Management can be viewed as a positive signal of confidence in Oric Pharmaceuticals, Inc.
Positives
- A prominent institutional investor, Point72 Asset Management, along with its affiliates, has disclosed a significant 5.1% beneficial ownership stake in Oric Pharmaceuticals, Inc., which can be interpreted as a signal of confidence in the company's prospects.
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates a significant institutional investment in Oric Pharmaceuticals, Inc., a common occurrence in the public markets where large asset managers take passive stakes in companies. It reflects a standard disclosure requirement for investors acquiring more than 5% of a company's shares.
Stakeholder Impact
- Shareholders may view the disclosure of a significant stake by Point72 Asset Management as a positive indicator of institutional confidence in Oric Pharmaceuticals, Inc.
Key Dates
| Date | Description |
|---|---|
| 04/28/2025 | Date as of which 71,088,080 shares outstanding were disclosed in Issuer's Quarterly Report on Form 10-Q. |
| 05/05/2025 | Date Issuer's Quarterly Report on Form 10-Q was filed with the SEC. |
| 05/28/2025 | Date Issuer's Current Report on Form 8-K was filed with the SEC, disclosing a private placement. |
| 05/29/2025 | Date of event which required the filing of this statement (closing of private placement). |
| 06/03/2025 | Date as of which beneficial ownership information is reported. |
| 06/04/2025 | Date of filing of the Schedule 13G. |
Keywords
Oric Pharmaceuticals, Point72 Asset Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investment, Passive Investment, Steven A. Cohen
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.